Biosimilar Growth Hormones Market Size Projected To Reach $1.19 Billion By 2034 With A Cagr Of 9.8%

The Biosimilar Growth Hormones Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Biosimilar Growth Hormones Market?
The biosimilar growth hormones market has seen strong growth in recent years. It will increase from $0.76 billion in 2024 to $0.82 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The historical growth is due to the rising demand for growth hormones, patent expirations, clinical evidence, and an increase in clinical trials.

The biosimilar growth hormones market is projected to experience strong growth, reaching $1.19 billion by 2029 with a CAGR of 9.8%. This expansion is driven by increased diagnoses, broader treatment indications, pediatric growth disorder management, and growing awareness of biosimilar treatments. Key trends include child-centric biosimilars, convenient dosing, and biosimilar combinations.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3391

What Are the Different Biosimilar Growth Hormones Market Segments?
The biosimilar growth hormones market covered in this report is segmented -

1) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular, Oral
2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics

Subsegments:
1) By Intravenous: Hospital-based Administration, Outpatient Clinics
2) By Subcutaneous: Self-administration, Professional Administration
3) By Intramuscular: Pediatric Care, Adult Care
4) By Oral: Tablets, Capsules

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3391&type=smp

What Are the Primary Drivers Shaping the Biosimilar Growth Hormones Market?
An increasing number of children diagnosed with growth hormone deficiency is driving the global biosimilar growth hormone market. This condition can result from congenital or acquired damage to the pituitary gland. According to Hormones Australia, as of September 2023, growth hormone deficiency affects 2 to 3 out of every 10,000 individuals, indicating a rising need for biosimilar hormone treatments.

Which Companies Are Leading in the Biosimilar Growth Hormones Market?
Major companies operating in the biosimilar growth hormones market include Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation

What Trends Are Expected to Dominate the Biosimilar Growth Hormones Market in the Next 5 Years?
Leading companies in the biosimilar growth hormones market are creating solutions like human growth hormone to improve treatment outcomes and affordability for individuals with growth hormone deficiencies. Growth hormone treatments help stimulate or replace human growth hormone (HGH) in the body for growth-related issues or anti-aging purposes. For example, in June 2023, Pfizer Inc. and OPKO Health Inc. received approval from the US Food and Drug Administration (FDA) for NGENLA (somatrogon-ghla), a once-weekly injectable human growth hormone designed for children with growth hormone deficiency (GHD). This long-acting therapy offers a convenient alternative to daily injections, improving patient adherence and convenience.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

What Are the Top Revenue-Generating Geographies in the Biosimilar Growth Hormones Market?
The countries covered in the biosimilar growth hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Biosimilar Growth Hormones Market?
2. What is the CAGR expected in the Biosimilar Growth Hormones Market?
3. What Are the Key Innovations Transforming the Biosimilar Growth Hormones Industry?
4. Which Region Is Leading the Biosimilar Growth Hormones Market?

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.